<DOC>
	<DOCNO>NCT01176006</DOCNO>
	<brief_summary>Background : -DOCK8 deficiency genetic disorder affect immune system lead severe recurrent infection possible death infection certain type cancer , include blood cancer . A stem cell transplant life-saving treatment condition . In study evaluate efficacy safety transplant different donor source DOCK8 deficiency . The donor use matched sibling , match unrelated donor , half-matched donor , call haploidentical related donor , mother father half-matched sibling . Objectives : -To determine whether transplant bone marrow cell different type donor corrects DOCK8 deficiency . Eligibility : - Donors : Healthy individual 4 60 year age match recipient . - Recipient : Individuals 5 40 year age DOCK8 deficiency , suffer one life-threatening infection , certain viral relate cancer cancer stem cell donor . Design : - All participant screen physical examination medical history . - DONORS : - Donors donate bone marrow cell blood stem cell . If donate blood stem cell , donor receive injection filgrastim release stem cell blood . After 5 day filgrastim injection , donor apheresis donate stem cell white blood cell present blood . - Donors provide stem cell bone marrow donation bone marrow cell harvest operating room . - RECIPIENTS : - Recipients receive match related unrelated donor receive 4 day chemotherapy busulfan fludarabine suppress immune system prepare transplant . Donors receive haploidentical related donor receive two dos chemotherapy cyclophosphamide , 5 day fludarabine , 3 day busulfan , one dose radiation suppress immune system prepare transplant . - After initial chemotherapy radiation , recipient receive donate stem cell single infusion . Recipients may also receive white blood cell stem cell donor encourage acceptance stem cell . - After stem cell transplant , recipient receive two day chemotherapy call cyclophosphamide day 's + 3 + 4 follow two drug tacrolimus mycophenolate prevent graft versus host disease donor cell attack patient 's body . All patient remain hospital approximately 1 month , follow regular visit 3 year periodic visit thereafter evaluate success transplant side effect .</brief_summary>
	<brief_title>Pilot Study Reduced-Intensity Hematopoietic Stem Cell Transplant DOCK8 Deficiency</brief_title>
	<detailed_description>Background Mutations Dedicator Cytokinesis-8 ( DOCK8 ) gene responsible immunodeficiency disease characterize : severe cutaneous sinopulmonary infection bacterial organism ; extensive cutaneous viral infection Herpes simplex , Herpes zoster , Molluscum contagiosum , Human Papilloma Virus ; mark elevation serum IgE level eosinophilia ; homozygous compound heterozygous mutation dedicator cytokinesis 8 ( DOCK8 ) gene . Patients DOCK8 deficiency die severe infection , squamous cell carcinoma , hematological malignancy . Allogeneic hematopoietic stem cell transplantation ( HSCT ) represent potentially life-saving treatment immunodeficiency diseases DOCK8 deficiency . In study evaluate efficacy safety allogeneic HSCT DOCK8 deficiency . We particularly interested determine whether allogeneic HSCT use different donor source condition regimen reverse lethal disease phenotype DOCK8 deficiency reconstitute normal host defense . The development lethal squamous cell carcinoma lymphoma arise immunodeficiency DOCK8 deficiency support therapeutic intervention overt malignancy arises . Objectives - To determine whether allogeneic HSCT reconstitute T-lymphocyte B-lymphocyte cell myeloid cell normal donor cell one year post-transplant revers clinical phenotype severe recurrent infection patient DOCK8 deficiency . - To determine safety allogeneic transplant regimen DOCK8 deficiency assess transplant relate toxicity , incidence acute chronic graft-versus-host disease , immune reconstitution , overall survival , disease-free survival - To determine whether post-transplant cyclophosphamide ( PT/CY ) result low incidence severity acute chronic GVHD compare standard methotrexate tacrolimus 10/10 match relate unrelated donor recipient . Eligibility Patients 5-40 year old DOCK8 deficiency suffer one life-threatening infection , develop lymphoma squamous cell carcinoma , 10/10 match related donor , 10/10 match unrelated donor , 9/10 match relate unrelated donor , haploidentical relate donor . Design -DOCK8 deficiency patient 10/10 match related donor unrelated donor receive pre-transplant conditioning regimen consist fludarabine 40 mg/m2/day day -6 , -5 , -4 , -3 , busulfan 3.2 mg/kg IV every day 4 day day -6 , -5 , -4 , -3 . The busulfan dose adjust base upon test dose busulfan give prior start condition regimen . Donor hematopoietic stem cell infuse day 0 . Post-transplant immunosuppression graft-versus-host-disease ( GVHD ) prophylaxis recipient 10/10 match relate unrelated donor consist cyclophosphamide 50 mg/kg IV daily 2 day day +3 +4 , along mycophenolate mofetil day +5 day +35 tacrolimus day +5 approximately day 180 . If evidence graft-versus-host disease , tacrolimus stop approximately day +180 . -DOCK8 deficiency patient 9/10 match related 9/10 match unrelated donor receive pre-transplant conditioning regimen consist cyclophosphamide 14.5 mg/kg day -6 -5 , fludarabine 30 mg/m2/day day -6 , -5 , -4 , -3 -2 , busulfan 3.2 mg/kg IV daily three day on-4 , -3 -2 , 200 cGy TBI day -1 . The busulfan dose adjust base upon test dose busulfan give prior start condition regimen . Donor hematopoietic stem cell infuse day 0 . Post-transplant immunosuppression graft-versus-host-disease ( GVHD ) prophylaxis recipient 9/10 match relate unrelated donor consist cyclophosphamide 50 mg/kg IV daily two day day +3 +4 , along mycophenolate mofetil day +5 day +35 tacrolimus day +5 day 180 . If evidence graft-versus-host disease , tacrolimus stop approximately day+180 . DOCK8 deficiency patient haploidentical related donor receive pre-transplant conditioning regimen consist cyclophosphamide 14.5 mg/kg day -6 -5 , busulfan 3.2 mg/kg IV daily 3 day day -4 , -3 , -2 , fludarabine 30 mg/m2 day -6 , -5 , -4 , -3 , -2 , 200 cGy TBI day -1 . The busulfan dose adjust base upon test dose busulfan give prior start condition regimen . Donor hematopoietic stem cell infuse day 0 . Post-transplant immunosuppression GVHD prophylaxis consist cyclophosphamide 50 mg/kg IV daily two day day +3 +4 , along mycophenolate mofetil day +5 day +35 tacrolimus day +5 day 180 . If evidence graft-versus-host disease , tacrolimus stop approximately day+180 .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>INCLUSION CRITERIA RECIPIENT : 1 . Patient age 540 year . 2 . DOCK8 deficiency two criterion list : Clinical history one episodes lifethreatening severely disfigure infection opportunistic organism , include severe recurrent cutaneous sinopulmonary infection bacterial fungal infection , viral infection herpes simplex , herpes zoster , Molluscum contagiosum , human papilloma virus . Homozygous compound heterozygous mutation DOCK8 gene perform CLIAcertified laboratory 3 . Available 10/10 9/10 HLAmatched relate unrelated donor haploidentical relate donor . 4 . Left ventricular ejection fraction &gt; 40 % , preferably 2D echo , obtain within 28 day enrollment . If patient radiological evidence aortic , renal artery , coronary artery vasculitis , leave ventricular ejection fraction &gt; 30 % acceptable . 5 . Pulmonary Function Tests : FEV1 great equal 20 % expect value obtain within 28 day enrollment . 6 . Creatinine : Patients : less equal 2.0 mg/dl creatinine clearance great equal 30 ml/min/1.73 m^2 . Pediatric patient ( &lt; 18 year old ) : Creatinine le equal 1.5 mg/dl creatinine clearance great equal 30 mL/min/1.73 m^2 . 7 . Serum total bilirubin &lt; 2.5 mg/dl ; serum ALT AST less equal 5 time upper limit normal . 8 . Adequate central venous access potential . 9 . Written inform consent/assent obtain patient/parent legal guardian . 10 . Disease status : Patients malignancy refer remission evaluation , except case viral associate malignancy . Should patient progressive disease donor become unavailable enrollment , patient refer back primary hematologistoncologist treatment . If course action best interest patient accord clinical judgment PI/LAI , patient may receive standard treatment malignant disease current study . If either setting , become apparent patient able proceed transplant , he/she must come study . RecipientSubjects receive standard therapy tell therapy , associate risk , benefit alternative propose therapy , availability receive treatment elsewhere , outside research protocol . EXCLUSION CRITERIA RECIPIENT : 1 . Patient age le 5 year old great 40 year old 2 . HIV infection . 3 . Chronic active hepatitis B . Patient may hepatitis B core antibody positive . For patient concomitant positive hepatitis B surface antigen , patient require hepatology consultation . The riskbenefit profile transplant hepatitis B discuss patient , eligibility determine PI protocol chairperson 4 . History psychiatric disorder may compromise compliance transplant protocol , allow appropriate inform consent . 5 . Active CNS involvement malignancy ( patient know positive CSF cytology parenchymal lesion visible CT MRI ) . Except case viral associate malignancy case patient may benefit transplant control malignancy . 6 . Pregnant lactating . The effect breastmilk also unknown may harmful infant ; therefore , woman breast feed interval study entry one year posttransplant . 7 . Sexually active individual capable become pregnant unable unwilling use effective form ( ) contraception time enrol study 1 year posttransplant . Effective form contraception include one following : intrauterine device ( IUD ) , hormonal ( birth control pill , injection , implant ) , tubal ligation/hysterectomy , partner vasectomy , barrier method , ( condom , diaphragm , cervical cap ) , abstinence . Males protocol must use effective form contraception study entry , one year posttransplant . The effect transplant , radiation , medication use transplant may harmful fetus . 8 . Presence active malignancy another organ system hematopoietic system , except drive virus case immune reconstitution transplant may control malignancy . 9 . No available 10/10 9/10 HLAmatched relate unrelated donor haploidentical relate donor . INCLUSION CRITERIA MATCHED RELATED DONOR : 1 . Related donor match HLAA , B , C , DR , DQ loci high resolution typing ( 10/10 antigen/allele match ) acceptable donor . Alternatively , 9/10 match related donor use . 2 . Ability give informed consent ; donor &lt; 18 year age , he/she must oldest eligible donor , legal guardian must give informed consent , donor must give verbal assent , he/she must clear social work mental health specialist participate . 3 . Age 460 year , weight great equal 15 kilogram . 4 . At least one normal DOCK8 allele demonstrate CLIAcertified lab . 5 . Adequate venous access peripheral apheresis , consent use temporary central venous catheter apheresis . 6 . Donors must HIV negative , hepatitis B surface antigen negative , hepatitis C antibody negative . This prevent possible transmission infection recipient . 7 . A donor lactating must willing able interrupt breastfeed substitute formula feed infant period filgrastim administration two day follow final dose . Filgrastim may secrete human milk , although bioavailability source know . INCLUSION CRITERIA MATCHED UNRELATED DONOR : 1 . Unrelated donor match 10/10 9/10 HLAA , B , C , DR , DQ loci high resolution type . 2 . The evaluation donor shall accordance exist NMDP Standard Policies Procedures . General donor inclusion criterion specify NMDP Standards . INCLUSION CRITERIA HAPLOIDENTICAL RELATED DONOR : 1 . A haploidentical donor share one haplotype common recipient HLA compatibility minimum 5 10 HLA locus match . The HLA locus test HLA A , B , Cw , DRB1 , DQB1 . A minimum number mismatch desirable ; however several option available selection donor base loci mismatch occur relative importance potential immunological function . Donorrecipient pair initially type molecularly provide low resolution typing ( antigenlevel ) aid selection potential donor . Upon review familial inheritance pattern , qualify HLA staff member review haplotype inheritance . High resolution ( allelelevel ) typing perform . Final selection donor consultation NCI physician qualify HLA personnel . If one haploidentical relate donor available , evaluate donor individually accord overall health , ABO matching , CMV , etc . select donor 2 . Age 460 year weight great equal 15 kilogram . 3 . At least one normal DOCK8 allele demonstrate CLIAcertified lab sibling donor . 4 . No history lifethreatening opportunistic infection 5 . Adequate venous access peripheral apheresis , consent use temporary central venous catheter apheresis . 6 . Donors must HIV negative , hepatitis B surface antigen negative , hepatitis C antibody negative . This prevent possible transmission infection recipient . 7 . Haploidentical donor undergo marrow harvest general anesthesia . Subjects undergo anesthesia consultation , meet criterion eligibility/enrollment . CD34+ fraction determine . 8 . Subjects also undergo Donor Health History Screen determine donor eligibility use standard DTM criterion Dowling Apheresis Clinic skilled staff Blood Services Section adult patient ageappropriate question indicate pediatric subject . 9 . Adult related donor would prefer related donor minor . 10 . Subjects undergo followup evaluation within 1 week donation . EXCLUSION CRITERIAMATCHED RELATED DONOR : 1 . Patient age le 4 year old great 60 year old . 2 . History severe cutaneous viral infection herpes simplex , herpes zoster , molluscum contagiosum . 3 . HIV infection . 4 . Chronic active hepatitis B. Donor may hepatitis core antibody positive . 5 . Other medical contraindication stem cell donation ( i.e . severe atherosclerosis , autoimmune disease , iritis episcleritis , deep venous thrombosis , cerebrovascular accident ) . 6 . History prior malignancy . However , cancer survivor undergo potentially curative therapy may consider stem cell donation casebycase basis . The risk/benefit transplant possibility transmit viable tumor cell time transplantation discuss patient . 7 . Donors must pregnant . Pregnancy absolute contraindication protocol . The effect cytokine administration fetus unknown . Donors childbearing potential must use effective method contraception . Effective form contraception include one following : intrauterine device ( IUD ) , hormonal ( birth control pill , injection , implant ) , tubal ligation/hysterectomy , partner vasectomy , barrier method , ( condom , diaphragm , cervical cap ) , abstinence . 8 . Other medical condition opinion PI constitute exclusion donor . 9 . Mutation DOCK8 allele . EXCLUSION CRITERIA MATCHED UNRELATED DONOR : ) Failure qualify NMDP donor . EXCLUSION CRITERIA HAPLOIDENTICAL RELATED DONOR : 1 . Age le 4 year old great 60 year old . 2 . HIV infection 3 . Chronic active hepatitis B. Donor may hepatitis core antibody positive . 4 . History psychiatric disorder opinion PI may compromise compliance transplant protocol , allow appropriate inform 5 . Other medical contraindication opinion PI constitute exclusion donor . History prior malignancy . However , cancer survivor undergo potentially curative therapy may consider stem cell donation casebycase basis . The risk/benefit transplant possibility transmit viable tumor cell time transplantation discuss patient . 6 . Donors must pregnant . Pregnancy absolute contraindication protocol . The effect cytokine administration fetus unknown . Donors childbearing potential must use effective method contraception . Effective form contraception include one following : intrauterine device ( IUD ) , hormonal ( birth control pill , injection , implant ) , tubal ligation/hysterectomy , partner vasectomy , barrier method , ( condom , diaphragm , cervical cap ) , abstinence . 7 . Mutation DOCK8 alleles sibling donor .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 1, 2016</verification_date>
	<keyword>DOCK8</keyword>
	<keyword>Molluscum</keyword>
	<keyword>Transplant</keyword>
	<keyword>Immunodeficiency</keyword>
</DOC>